newsfilter
← Latest News
GlobeNewswire·

Small Pharma Announces SPL028 R&D Strategy Update

• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from Company's native DMT program, SPL026,